Replies to post #246760 on Avid Bioservices Inc (CDMO)

[senrex]

Biopharm, shouldn't that NASD Rule 2711 that you highlighted in red make us a tad nervous? As it read it, Piper Jaffrey must have materially substantive reasons for terminating coverage of a company they know so much about, and that they would be in trouble if it were for a reason such as "pique" with PPHM as has been suggested. Am I missing something? TIA.

[Protector]

biopharm, this opens another possibility.

We have seen Zavoico move away in the past. Maybe Duncan leaves Piper Jaffray's. As posted by others PPHM was on PJ's main lists but no longer in Charles Duncan's.

The report must be comparable in scope and detail to prior research reports and must include a final recommendation or rating, unless it is impracticable for the member to produce a comparable report (e.g., if the research analyst covering the subject company or sector has left the member or if the member terminates coverage of the industry or sector).

Then again Charles Duncan's list should be empty altogether.